| Nov 21 |
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
|
| Nov 16 |
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
|
| Nov 8 |
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?
|
| Nov 8 |
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)
|
| Nov 7 |
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 5 |
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 5 |
AnaptysBio GAAP EPS of -$1.14 beats by $0.51, revenue of $30.02M beats by $21.85M
|
| Nov 5 |
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 5 |
Anaptys Announces Participation in November and December Investor Conferences
|
| Nov 1 |
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
|
